MedTrace Logo

A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

NCT01609933 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-06-19

Study results available
· View outcomes & findings →

Summary

A study to evaluate the safety and effect of treatment with experimental antiviral drugs in combination with peginterferon alpha-2a and ribavirin in people with hepatitis C virus who did not respond to treatment in a previous AbbVie/Abbott combination study.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

ABT-450/r

ABT-450 (tablets) dosed with ritonavir (capsules or tablets)

DRUG

ABT-267

ABT-267 (tablets)

DRUG

pegylated interferon alpha-2a (pegIFN)

pegIFN alpha-2a (syringe)

DRUG

Ribavirin (RBV)

Ribavirin (tablets)

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • AbbVie Inc. · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
71 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-18
Primary Completion
2017-05-03
Completion
2017-05-03
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01609933 on ClinicalTrials.gov